You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國同輻(01763.HK):上半年歸母淨利潤1.55億元 同比增長23.2%
格隆匯 08-30 19:01

格隆匯8月30日丨中國同輻(01763.HK)公佈中期業績,2024年上半年,集團持續加大市場開拓力度,主動作為搶抓市場機遇,各項經濟指標實現提升。報吿期內,集團實現收益人民幣28.103億元,同比增長2.6%;實現淨利潤人民幣3.067億元,同比增長8.7%,歸屬於公司權益股東淨利潤人民幣1.55億元,同比增長23.2%。董事會議決向股東建議宣派截至2024年6月30日止六個月期間的中期股息,每股派發現金股息人民幣0.0724元(含税)。

報吿期內,集團率先推出業內首個智慧核醫學整體解決方案和“輻智1.0”智慧核醫學管理系統,並於6月底在北京協和醫院完成整體上線驗收,建成全球首個國家級智慧核醫學示範中心。同時,在新疆、四川、浙江、廣東、福建等重點省份積極推進區域專科聯盟和示範基地建設。上半年舉辦廣東省核醫療研發應用聯盟研討會,推動廣東省“頂天立地”產學研醫一體化平台建立。核醫療研發應用聯盟,是催生培育新質生產力的創新機制和高效組織方式,將政、產、學、研、醫、用聚集起來,搭建了信息交流、資源共享、聚力攻克重大困難的平台。上半年成立四川省攀西地區核醫學專科聯盟,推動攀西地區核醫學事業步入發展快車道。智慧核醫學整體解決方案在新疆維吾爾自治區中醫院實現首個合同訂單零突破,新簽署4家省級三甲醫院戰略合作協議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account